In response to the COVID-19 pandemic, the Food and Drug Administration ("FDA") recently released and revised the guidelines on the use of electronic prescription in order to ensure the safety of individuals who are highly vulnerable to the virus.
In the article entitled: “e-Rx: FDA Reissues Guidelines on the Use of Electronic Prescriptions,” Villaraza & Angangco's Ma. Sophia Editha C. Cruz-Abrenica and Maria Patricia P. Cruz discuss the guidelines on the use of electronic prescription as reissued recently by the FDA and review the details of the memorandum as revised, covering the objectives, scope and coverage, required information in the e-prescription, and the period of effectivity.
Access the article as published on Lexology here: https://www.lexology.com/library/detail.aspx?g=387391fe-c6fc-498c-b4c5-458e5bc133fd
